Skip Nav Destination
Issues
1 January 2010
-
Cover Image
Cover Image
Targeting Cdk-2 in lung cancer was found to engage a previously unrecognized mechanism: induced anaphase catastrophe. This triggers apoptosis in lung cancer cells. The immunofluorescent image of a representative lung cancer cell is shown following small interfering RNA targeting of Cdk-2. In this image, microtubules are displayed in red and DNA in blue within a multipolar lung cancer cell undergoing anaphase catastrophe. For further details, please see the article by Galimberti and colleagues on page 109 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Review
Human Cancer Biology
Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Carole Tarpin; Mark Diebel; Benjamin Esterni; Gilles Houvenaeghel; Jean-Marc Extra; François Bertucci; Jocelyne Jacquemier; Luc Xerri; Gabriela Dontu; Giorgio Stassi; Yi Xiao; Sanford H. Barsky; Daniel Birnbaum; Patrice Viens; Max S. Wicha
Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer
Alexander T. El Gammal; Michael Brüchmann; Jozef Zustin; Hendrik Isbarn; Olaf J.C. Hellwinkel; Jens Köllermann; Guido Sauter; Ronald Simon; Waldemar Wilczak; Jörg Schwarz; Carsten Bokemeyer; Tim H. Brümmendorf; Jakob R. Izbicki; Emre Yekebas; Margit Fisch; Hartwig Huland; Markus Graefen; Thorsten Schlomm
Inhibitor of Differentiation 1 Contributes to Head and Neck Squamous Cell Carcinoma Survival via the NF-κB/Survivin and Phosphoinositide 3-Kinase/Akt Signaling Pathways
Jizhen Lin; Zhong Guan; Chuan Wang; Ling Feng; Yiqing Zheng; Emiro Caicedo; Ellalane Bearth; Jie-Ren Peng; Patrick Gaffney; Frank G. Ondrey
Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer
Corinne Dahinden; Barbara Ingold; Peter Wild; Gunther Boysen; Van-Duc Luu; Matteo Montani; Glen Kristiansen; Tullio Sulser; Peter Bühlmann; Holger Moch; Peter Schraml
Cancer Therapy: Preclinical
Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment
Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S. Dimitrov; Seiichi Saito; Atsushi Ochiai
Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Devalingam Mahalingam; Ernest C. Medina; Juan A. Esquivel, II; Claudia M. Espitia; Sabrina Smith; Kelli Oberheu; Ronan Swords; Kevin R. Kelly; Monica M. Mita; Alain C. Mita; Jennifer S. Carew; Francis J. Giles; Steffan T. Nawrocki
The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth
Calin O. Marian; Steve K. Cho; Brian M. Mcellin; Elizabeth A. Maher; Kimmo J. Hatanpaa; Christopher J. Madden; Bruce E. Mickey; Woodring E. Wright; Jerry W. Shay; Robert M. Bachoo
Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor β–Insensitive CD8+ T Cells
Longxin Wang; Weihong Wen; Jianlin Yuan; Brian Helfand; Yu Li; Changhong Shi; Feng Tian; Jia Zheng; Fuli Wang; Lin Chen; Lili Liang; Liqun Zhou; Chung Lee; Zhinan Chen; Yinglu Guo; He Wang; Qiang Zhang; Weijun Qin
c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer
Pablo Vivas-Mejia; Juliana Maria Benito; Ariel Fernandez; Hee-Dong Han; Lingegowda Mangala; Cristian Rodriguez-Aguayo; Arturo Chavez-Reyes; Yvonne G. Lin; Mark S. Carey; Alpa M. Nick; Rebecca L. Stone; Hye Sun Kim; Francois-Xavier Claret; William Bornmann; Bryan T.J. Hennessy; Angela Sanguino; Zhengong Peng; Anil K. Sood; Gabriel Lopez-Berestein
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer
George R. Blumenschein, Jr.; Karen Reckamp; G. Joe Stephenson; Timothy O'Rourke; Gregory Gladish; Jesse McGreivy; Yu-Nien Sun; Yining Ye; Mandy Parson; Alan Sandler
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
B. Douglas Smith; Yvette L. Kasamon; Jeanne Kowalski; Christopher Gocke; Kathleen Murphy; Carole B. Miller; Elizabeth Garrett-Mayer; Hua-Ling Tsai; Lu Qin; Christina Chia; Barbara Biedrzycki; Thomas C. Harding; Guang Haun Tu; Richard Jones; Kristen Hege; Hyam I. Levitsky
A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets
Yingjun Su; Katayoun I. Amiri; Linda W. Horton; Yingchun Yu; Gregory D. Ayers; Elizabeth Koehler; Mark C. Kelley; Igor Puzanov; Ann Richmond; Jeffrey A. Sosman
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
William P. Tew; Michael Gordon; John Murren; Jakob Dupont; Sandra Pezzulli; Carol Aghajanian; Paul Sabbatini; David Mendelson; Lawrence Schwartz; Scott Gettinger; Amanda Psyrri; Jesse M. Cedarbaum; David R. Spriggs
Letters to the Editor
Correction
Highlights
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds